• Lung cancer is the most frequently diagnosed cancer worldwide.
• Survival remains poor for those with inoperable disease (median 28 months).
• Whilst the role of curative-intent radiotherapy (RT) is widely accepted, the thorax remains a challenging anatomical site to irradiate.
• New advanced radiotherapy technologies; stereotactic ablative radiotherapy (SABR), magnetic resonance image-guided radiotherapy (MR-Linac) and proton-beam therapy (PBT) have potential to yield substantial clinical benefits.
• However there are significant challenges for development, assessment and rational implementation within the NHS. 
ART-NET Goals:
• Accelerate clinical translation of SABR, MR-Linac and PBT around the theme of hypofractionated RT to provide an evidence based rationale across a range of tumour types.
• Develop/disseminate expertise in medical physics to lead development of planning/image guided solutions for these technologies.
• Implement methodologies for reliable treatment plan optimization on MR-images, acquired directly prior to or during treatment, enabling the clinical benefit of MR-guided SABR and MR-Linac to be fully exploited.
• Co-ordinate methodological developments in design and conduct of clinical trials to streamline assessments of new health technologies in specific tumours.
Conclusion:
• A key aim of ART-NET is to generate national treatment protocols and disseminate them across the UK, improving and harmonising practice. 2 • Additionally, involvement of medical physicists, research radiographers and clinical research fellows in ART-NET will develop a skilled workforce that will be a huge asset for future radiotherapy research in the UK.
• Ultimately this will improve patient access to state-of-the-art radiotherapy and increase recruitment into clinical trials.
WORKSTREAMS Traffic light protocol:
• This is a project being undertaken within the motion management workstream 3 and is based on the traffic light system developed at the NKI (see fig 1) . 1 • The aim is to develop a protocol to facilitate online radiographer review of cone beam computerised tomography (CBCTs) in patients undergoing lung SABR to assess organ motion and anatomical changes. • This will assess the impact of these changes on PTV coverage and advise when to seek physics/clinical review. • This will inform the need for plan adaptation nationally.
2 Fast/adaptive re-planning
• Provide QA guidance for MR and image registration software to enable the use of MR in SABR.
• Standardise algorithms that generate synthetic CT images from treatmentintegrated MR images for all tumour sites and applied imaging protocols.
• Implement image processing tools to allow verification of the geometrical accuracy of the acquired MR images.
• Share tools to generate images suitable for dose calculations from online images (CBCT, MR).
• Implement fast segmentation tools across the network.
• Disseminate ultra-fast Monte-Carlo dose algorithms for photon and proton beams.
• Multi-site implementation of a high-performance inverse planning tool exploiting modern computational CPU and GPU hardware architectures.
• Image library-based (3-D, 4-D) quantification of organ motion and anatomical changes in tumour and adjacent critical structures.
• Evaluation of novel 4-D acquisition, reconstruction, and motion modelling approaches and determine their suitability for clinical use.
• Quantification of treatment platform-independent uncertainties (e.g. delineation variability and short-term organ motion) and their effect on predictions of tumour/normal organs motion.
• Evaluation of the accuracy of image-guidance methodologies for each treatment platform.
Health economics
• Development of MRI-based early predictors of radiotherapy response.
• Design of one prospective validation study to demonstrate that predictors of response have utility in a multi-site and multi-vendor trial.
• Recommendations for development pathways for new RT technologies into practice-changing clinical trials.
• Assess feasibility/delivery of PBT and MR-Linac clinical trials including assessment of logistics and equipoise.
• Development of core outcome set; treatment, dosimetry, safety, efficacy, effectiveness, including electronic platforms for patient-reported outcomes.
• Support for clinical trial grant applications in core TSGs.
• Protocol for correction of range differences at all PBT centres.
• In silico validation of protocol to assess proton range using motion management system.
• Evaluate proton range verification techniques and identify margins for complex treatments.
• Development of health economic methodology.
• Comparative assessment of SABR, PBT and MR-Linac for prostate cancer.
• Comparative assessment of SABR, PBT and MR-Linac for second site (e.g. lung, oesophagus). First row: level red change; T4N2M0 NSCLC; CBCT of week 3, the atelectasis resolved and this resulted in a tumour shift outside PTV.
Second row: level orange change; T4N2M0 NSCLC; week 1 CBCT showed atelectasis without a tumour shift.
Third row: level yellow change; T4N2M0 NSCLC; CBCT shows regression in week 3 of the treatment.
Fourth row: level green; CBCT shows no change at fraction 15.
